---
title: "Varegacestat (AL102) in Desmoid tumors: Effects of other drugs"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Effects of other drugs. Topics: Itraconazole interaction study in healthy participants and CYP3A4 and P-glycoprotein inhibitors and inducers as prohibited concomitant medications. 2 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Varegacestat

<a id="topic-2.1.2.9.1-1"></a>

### Itraconazole interaction study in healthy participants

> “This is a phase 1, open-label, fixed sequence, 1-way crossover study examining the effect of itraconazole on the pharmacokinetics, safety and tolerability after varegacestat single dose administration to healthy participants. This is a 2-period study. In period 1 a single dose of varegacestat will be administered with PK evaluated predose and up to 192 hours postdose. There will be a 14 -day washout between period 1 and period 2. In period 2, itraconzole will be administered once daily for 18 consecutive days. Beginning on Day 4 of Period 2 a single dose of varegacestat will be administered 30 minutes after itraconazole dosing. Blood samples for PK will be collected prior to varegacestat dosing and up to 744 hours post varegacestat dosing for varegacestat and its metabolite.”
> “Itraconazole (200 mg)”
> “AUC0-t for varegacestat administered with and without itraconazole.”
> “AUC0-inf for varegacestat administered with and without itraconazole.”
> “Cmax for varegacestat administered with and without itraconazole.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-2.1.2.9.1-2"></a>

### CYP3A4 and P-glycoprotein inhibitors and inducers as prohibited concomitant medications

> “The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
